Reinthaler Markus, Aggarwal Sunil K, De Palma Rodney, Landmesser Ulf, Froehlich Georg, Yap John, Meier Pascal, Mullen Michael J
Department of Cardiology, The Heart Hospital University College London Hospitals; London-England.
Anatol J Cardiol. 2015 Apr;15(4):297-305. doi: 10.5152/akd.2014.5311. Epub 2014 Apr 28.
This study aimed to investigate the predictive value of circumferential iliofemoral calcifications and current manufacturer recommendations, which are not evidence-based, in transfemoral (TF) transcatheter aortic valve implantation (TAVI).
A patient cohort with a broad range of iliofemoral anatomies undergoing TF TAVI (n=132) were retrospectively divided as "suitable" (n=76, 58%) and "unsuitable" (n=56, 42%) candidates according to current recommendations. Iliofemoral angiography and reconstructed multislice CT (MSCT) images were used for access screening in the majority of patients.
Vessel properties were significantly worse in the "unsuitable group." The sheath-to-iliofemoral artery ratio (SIFAR) and calcium score were 1.35±0.2 and 1.7±0.8 in the unsuitable group, compared to 1.0±0.12 (p<0.0001) and 1.0±0.7 (p=0.0001) in the "suitable" patients. Major vascular complications (MVCs) occurred more frequently in the "unsuitable" group (10.7% vs. 2.6%, p=0.07) and were predicted by SIFAR [OR: 64, 95% CI: 1.4-2971, p=0.03] and circumferential iliofemoral calcifications [OR: 6, 95% CI: 1.2-26, p=0.025]. In the multivariate analysis, circumferential calcifications [HR: 3.6, 95% CI: 1-13.2, p=0.043] but not major vascular complications (MVCs) or manufacturer recommendations were associated with increased mortality.
According to our results, manufacturer recommendations are safe but overly conservative. Circumferential iliofemoral calcifications may provide independent prognostic information in patients undergoing TAVI.
本研究旨在探讨股髂周向钙化及当前制造商未基于证据的推荐意见在经股动脉(TF)经导管主动脉瓣植入术(TAVI)中的预测价值。
对一组接受TF TAVI的具有广泛股髂解剖结构的患者队列(n = 132)进行回顾性研究,根据当前推荐意见将其分为“合适”(n = 76,58%)和“不合适”(n = 56,42%)两组。大多数患者采用股髂血管造影和重建多层螺旋CT(MSCT)图像进行入路筛选。
“不合适组”的血管特性明显较差。不合适组的鞘管与股髂动脉比值(SIFAR)和钙化评分分别为1.35±0.2和1.7±0.8,而“合适”患者分别为1.0±0.12(p<0.0001)和1.0±0.7(p = 0.0001)。“不合适组”主要血管并发症(MVCs)的发生率更高(10.7%对2.6%,p = 0.07),且SIFAR[比值比(OR):64,95%置信区间(CI):1.4 - 2971,p = 0.03]和股髂周向钙化[OR:6,95% CI:1.2 - 26,p = 0.025]可预测其发生。在多因素分析中,周向钙化[风险比(HR):3.6,95% CI:1 - 13.2,p = 0.043]而非主要血管并发症(MVCs)或制造商推荐意见与死亡率增加相关。
根据我们的研究结果,制造商的推荐意见是安全的,但过于保守。股髂周向钙化可能为接受TAVI的患者提供独立的预后信息。